EyeTechCare, based in Rillieux-la-Pape, France, has received $13 million in funding from private investor Bernard Chauvin, insurer SHAM and Omnes Capital.
EyeTechCare creates non-invasive ophthalmological devices, including the ultrasound-based glaucoma treatment device, EyeOP1.
The $13 million in funding will be used to finance the international clinical trial and start of FDA clearance for EyeOP1.
More Articles on Ophthalmology:
Boston Micromachines Receives $1.2M NIH Grant for Retinal Imaging System
Dr. Andrew Holzman to Participate in FDA Trial
$2M in NIH Funds Helps Researchers Combat Diabetic Related Vision Loss
EyeTechCare creates non-invasive ophthalmological devices, including the ultrasound-based glaucoma treatment device, EyeOP1.
The $13 million in funding will be used to finance the international clinical trial and start of FDA clearance for EyeOP1.
More Articles on Ophthalmology:
Boston Micromachines Receives $1.2M NIH Grant for Retinal Imaging System
Dr. Andrew Holzman to Participate in FDA Trial
$2M in NIH Funds Helps Researchers Combat Diabetic Related Vision Loss